spacer
home > epc > winter 2018 > marking safety
PUBLICATIONS
European Pharmaceutical Contractor

Marking Safety

“Sepsis is the most preventable cause of death” (1), and every hour it is not diagnosed will increase the probability of killing the patient by 7%; thus, recognising the early signs and symptoms is crucial. Severe sepsis is the leading cause of death in the noncoronary intensive care unit, with mortality rates between 30-50%.

According to Dr Adam Linder, “approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours” (2). Furthermore, it is also the biggest killer of children under five worldwide. Konrad Reinhart notes that 6 million babies from third-world countries and 10,000 of mothers die from the condition every year (1).

As sepsis often impacts the elderly (usually when they have some other condition), it is perhaps less talked about, but it also affects children. With such susceptible groups as these, anything that raises awareness among medical staff of the signs, symptoms, and dangers can only be a good thing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University in Australia and achieved a Professor of Medicine and Life Sciences at Bond University Queensland in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a Principal Investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

POP TEST ADDRESSES THE PROBLEM OF UNRELIABLE DATA FROM CONTINUOUS GLUCOSE MONITORS

A major insight relating to the unreliability of data from continuous glucose monitors was published in the Nature journal, “Scientific Reports”, by Neil Theise, MD., the Lead Scientist of Pop Test, LLC and colleagues. The discovery of the “Interstitium”, a newfound human organ, by Dr. Theise and his collaborators, can be viewed by using the link https://www.nature.com/articles/s41598-018-23062-6 Continual glucose monitoring via an indwelling cutaneous needle measuring glucose in interstitial fluid (now identified to be in the “interstitium”) has been a game changer in the treatment of type 1 diabetes mellitus because of its accuracy. However, the needles used to collect this glucose containing fluid often fail in as little as a week. Despite the reliance on fluid from this space, the microanatomy of the interstitium has never been defined. The sensors currently in use were developed with the presumption of interstitial fluid being located somewhere in the sub-epidermal layers of the skin, but the actual anatomy relating to needle placement was always unclear.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

Clinical Trial Supply Nordics 2018

19-20 June 2018, Copenhagen, Denmark

Building on last year’s success, our CTS team have conducted extensive research to ensure the 2018 event programme covers all the essentials in clinical supply. In the current climate, every pharma and biotech company are trying to reduce unwanted costs, and enhance operational efficiency. To avoid costly setbacks, an innovative and effective strategy needs to be implemented!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement